regularly on drugs such as theophylline, estrogen or calcium channel blockers, deranged hematological/renal/hepatic laboratory parameters, and parents not willing for participation.
Considering the expected toxicity thrombocytopenia which was 8.3% (Kinney et al. [4] ) precision 10%, desired confidence level (1−α) 95%, minimum sample size required was 30 with 10% lost to follow up. Total sample size required was 33. However, 40 subjects were enrolled.
Required sample size (n):
n=33, p=Expected toxicity, d=Absolute precision, α=Significance level=5%, Z 1−α/2 =1.96.
At enrollment, a detailed history of previous symptoms, hospitalizations, blood transfusion rate, frequency of vaso-occlusive crises, acute painful events, acute chest syndrome, avascular necrosis of femur, and stroke was elicited. The same was noted on follow-up visits. The laboratory parameters assessed at baseline and follow-up visits were hemoglobin (Hb), absolute neutrophil count (ANC), ARC, platelet count (Plt. C), hemoglobin F (HbF) level and serum glutamic-pyruvic transaminase (SGPT)/alanine aminotransferase (ALT), and serum creatinine level. Enrolled cases were treated with HU in a fixed dose of 10 mg/kg once daily. During the follow-up visits, cases were evaluated for compliance of HU, its toxic effects, adverse events from histories, and clinical examination. HbF levels were estimated after the completion of 2 years of HU therapy.
Hematological toxicity was defined as one or more of the following: (i) Hb -20% decrease from entry/previous value or Hb <4.5 g/dl, (ii) ANC <2.0 × 10 3 /mm 3 , (iii) ARC <80 × 10 3 /mm 3 unless Hb was 9.0 g/dl or higher, and (iv) Plt. C <80 × 10 3 /mm 3 .
Biochemical toxicity was defined as Hepatic toxicity ALT/SGPT >twice the upper limit of baseline renal toxicity serum creatinine >1.0 mg/dl. Any toxicity or minor adverse drug events were managed as per the standard protocols [4] . HU when withheld for mean duration of 2 weeks period and restarted at the same dose after normalization of the deranged laboratory parameters. Statistical software STATA version 10.0 was used for statistical analysis.
RESULTS
In this study, most children belonged to 12-15 years (55%), 9-11 years (22.5%), and 5-8 years (22.5%) age groups. There were 22 (55%) males and 18 (45%) females belonging to Mahar, Teli, Kunbi, Muslim, and Gond community. Indications to start Hydroxyurea were the acute painful events ≥2/year requiring hospitalization (52.5%), frequent blood transfusions ≥3/year (27.55%), stroke (15%), acute chest syndrome (2.5%), and avascular necrosis of femur (2.5%). Out of 40 cases, 36 (90%) cases had completed regular monthly follow-up for 2 years while 4 (10%) cases were lost to follow up. Further, statistical analysis was performed on 36 cases only.
During hydroxyurea therapy, clinical events and toxicities were noted as shown in Table 1 . The clinical adverse drug events observed in our study were nausea in 3 cases (8.33%), diarrhea in 1 (2.78%), and hematuria in 1 case (2.78%).
As shown in Table 2 , the mean acute painful events and blood transfusions rates reduced significantly at the end of 2 years of HU therapy (p=0.001). No recurrence of acute chest syndrome or occurrence of stroke event was seen. The mean Hb and mean HbF level increased significantly after HU therapy. The reduction in mean acute painful events statistically correlated with rising mean HbF level after HU therapy (correlation coefficient=0.3954, p=0.0170), as shown in Fig. 1 .
DISCUSSION
Many studies demonstrated a beneficial effect of HU in SCD children [4] [5] [6] . Our study included 5-15-year-old SCD patients with severe painful crisis (>3 vaso-occlusive events/year) similar to the studies done by Kinney et al. [4] , Scot et al. [6] , and Ferster et al. [8] . In the present study, HU was given in a single fixed dose of 10 mg/kg/day orally without escalation due to fear of toxicity in pediatric age group. Similarly, Italia et al. [9] used HU 10 mg/kg/d and increased it up to 15 mg/kg/d. Lima et al. [10] used HU in an escalation dose of 10-20 mg/kg/d. Patel et al. [11] undertook study with minimal dose of HU (10 mg/kg/d) in pediatric and adult SCD patients. Kinney et al. [4] in HUG-KIDS study used initial single oral dose of 15 mg/kg/d, which were increased by 5 mg/kg/d, if no toxicity was seen and the mean dose was 26.6±6.2 mg/kg/d. Tshilolo et al. [12] demonstrated safety and beneficial effects of HU in sickle cell anemia children in sub-Saharan Africa in a mean dose of 17±1.8 mg/kg/d. Opoka et al. compared HU (20±2.5 mg/kg/d) to placebo for 12 months and concluded that HU was safe for SCD children of sub-Saharan Africa, without increased severe malaria, infections, or adverse events [13] .
In our study, transient clinical adverse drug events were nausea (8.33%), diarrhea (2.78%), and hematuria (2.78%). Kinney et al. [4] also observed similar adverse clinical events. Jayabose et al. [14] also reported nausea in their study of HU in sickle cell anemia. In the present study, anemia was the most common transient hematological toxicity followed by thrombocytopenia and neutropenia. However, reticulocytopenia was not observed. Hematological toxicity was common and transient in nature as reported in many previous studies [4] [5] [6] [14] [15] [16] [17] . Kinney et al. [4] reported various cytopenias, namely, anemia, reticulocytopenia, neutropenia, and thrombocytopenia from HU. Thrombocytopenia was reported in the studies by other authors also [8, [16] [17] [18] .
Renal toxicity occurred in four and hepatic toxicity in three cases in our study. All these toxicities were transient requiring temporary discontinuation of HU. Hepatotoxicity was also reported in studies done by Kinney et al. [4] and Wang et al. [18] . Renal toxicity was not reported in most of the studies. Odievre et al. [7] mentioned that a 13-year-old girl developed acute renal failure when systemic lupus erythematous syndrome occurred and required hemodialysis and definitive cessation of HU treatment. PED-HUG study by Kinney et al. [4] showed that the effects of HU on kidney and liver functions were negligible during the study. All our cases were alive and no case of malignancy/leukemia or sustained myelosuppression was observed.
In our study, we found a significant reduction in the number of acute painful events/year/person and mean blood transfusions rate after HU therapy and similar observations were made in the previous studies also [4, 6, [8] [9] [10] [11] 16, 19, 20] . We also found a significant increase in HbF at the end of 2 years of HU therapy and the rise significantly correlated with the reduction of the painful events. Ferster et al. [15] showed that mean HbF in SCD pediatric patients on HU therapy raised from 4.7% to 15%. Similar rise in HbF was observed by other authors also [4, [9] [10] [11] 21] . 
